|Application ||WB, IHC-P, E|
|Calculated MW||40780 Da|
|Antigen Region||324-353 aa|
|Other Names||Melanoma-associated antigen 10, Cancer/testis antigen 110, CT110, MAGE-10 antigen, MAGEA10, MAGE10|
|Target/Specificity||This MAGEA10 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 324-353 amino acids from the C-terminal region of human MAGEA10.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||MAGEA10 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression.|
|Tissue Location||Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for spermatogonia, spermatocytes and placenta|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MAGEA10 is a member of the MAGEA gene family. The members of this family have their entire coding sequences located in the last exon, and the encoded proteins show 50 to 80% sequence identity between each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are expressed at a high level in a number of tumors of various histologic types, and are silent in normal tissues with the exception of testis and placenta. The MAGEA genes are clustered on chromosome Xq28. They may be implicated in some hereditary disorders, such as dyskeratosis congenita.
Rogner, U.C., et al., Genomics 29(3):725-731 (1995).
De Plaen, E., et al., Immunogenetics 40(5):360-369 (1994).
If you have any additional inquiries please email technical services at email@example.com.